NW-101

N/A

Report date: 2025/01/08 15:16:18

Base Information

Drug NameNW-101
Drug Alias NameNW-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionTumor-associated antigen modulators
TargetsTumor-associated antigen
Therapy Area/IndicationsEndometrial NeoplasmsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesNeowise Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeowise Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A